Indivior Pharmaceuticals, Inc. (INDV)
As-reported financials and SEC filings for Indivior Pharmaceuticals, Inc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. develops and markets long-acting injectable medications and other pharmacotherapies for opioid use disorder (OUD). Its main products include SUBLOCADE, a monthly buprenorphine injection, and SUBOXONE Film, a buprenorphine and naloxone sublingual film, primarily sold in the U.S. The company serves patients with OUD and healthcare providers, with additional product availability in Canada, Australia, France, and Germany.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Indivior Pharmaceuticals
- Revenue grew 4.3% to $1.2B in FY2025, slower than the 8.7% the year before.
- Most recent quarter Q2 FY2026: revenue $343M, up 13.6% from Q2 FY2025.
- Free cash flow was negative $93M in FY2025.
- Net income rose more than tenfold to $210M in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Indivior Pharmaceuticals’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
2 reported insider purchases (code P) totaling $107,955 in the last 90 days, against 3 sales totaling $2.8M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 2 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| Citadel Advisorsquant | Q2 2026 | $109.5M | 2.7M | Reduced |
| Millennium Managementquant | Q2 2026 | $86.1M | 2.1M | Reduced |
| Point72 Asset Managementquant | Q2 2026 | $51.3M | 1.3M | Added |
| Two Sigma Investmentsquant | Q2 2026 | $12.8M | 312.0K | Added |
| D. E. Shawquant | Q2 2026 | $9.7M | 236.0K | Added |
| AQR Capital Managementquant | Q2 2026 | $8.8M | 213.9K | Reduced |
| Gotham Asset Management | Q2 2026 | $3.9M | 94.8K | New |
| Bridgewater Associates | Q2 2026 | $2.8M | 68.2K | Added |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-08-27 | Anderson Woodrow DChief Accounting Officer | Buy | 1.5K | $35.69 | $54K |
2026-08-05 | Anderson Woodrow DChief Accounting Officer | Buy | 1.5K | $36.28 | $54K |
2026-07-10 filed 2026-07-13 | Heidbreder ChristianChief Scientific Officer | Sell | 18.6K | $41.14 | $765K |
2026-06-11 filed 2026-06-12 | Heidbreder ChristianChief Scientific Officer | Sell | 18.6K | $38.06 | $707K |
2026-06-08 filed 2026-06-10 | Preblick RyanChief Financial Officer | Sell | 36.0K | $37.70 | $1.4M |
Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-14 | 10.4M | -4.0% | 3.27 |
| 2026-07-31 | 10.9M | -3.5% | 7.13 |
| 2026-07-15 | 11.3M | +4.6% | 7.58 |
| 2026-06-30 | 10.8M | -9.0% | 4.66 |
| 2026-06-15 | 11.9M | -6.4% | 7.12 |
| 2026-05-29 | 12.7M | -7.8% | 7.73 |
| 2026-05-15 | 13.7M | +7.1% | 5.34 |
| 2026-04-30 | 12.8M | -7.9% | 6.81 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B | $901.0M | — |
| Gross profit | $993.0M | $957.0M | $919.0M | $750.0M | — |
| Operating income | $262.0M | $38.0M | $-152.0M | $-81.0M | — |
| Net income | $210.0M | $7.0M | $-126.0M | $-44.0M | — |
| Diluted EPS | $1.64 | $0.05 | $-0.92 | $-0.32 | — |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $195.0M | $319.0M | $316.0M | $774.0M | $1.10B |
| Current assets | $652.0M | $827.0M | $1.26B | — | — |
| Total assets | $1.20B | $1.32B | $1.76B | — | — |
| Current liabilities | $914.0M | $924.0M | $1.28B | — | — |
| Long-term debt | $290.0M | $315.0M | $237.0M | — | — |
| Total liabilities | $1.30B | $1.65B | $1.94B | — | — |
| Total equity | $-98.0M | $-337.0M | $-184.0M | $-15.0M | $121.0M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $-27.0M | $36.0M | $-300.0M | $-4.0M | — |
| Capital expenditure | $66.0M | $29.0M | $8.0M | $5.0M | — |
| Free cash flow | $-93.0M | $7.0M | $-308.0M | $-9.0M | — |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q2 FY2026 | $343.0M | 13.6% | $122.0M | $0.98 |
| Q1 FY2026 | $317.0M | 19.2% | $89.0M | $0.69 |
| Q4 FY2025 | $358.0M | — | $102.0M | $0.78 |
| Q3 FY2025 | $314.0M | 2.3% | $42.0M | $0.33 |
| Q2 FY2025 | $302.0M | 1.0% | $18.0M | $0.14 |
| Q1 FY2025 | $266.0M | -6.3% | $47.0M | $0.38 |
| Q4 FY2024 | — | — | $21.0M | — |
| Q3 FY2024 | $307.0M | — | $22.0M | $0.16 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Selected SEC filings
Largest pharmaceutical peers
Monitor INDV
Get an alert when Indivior Pharmaceuticals files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor INDV freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.